Drug Profile

SBT 101

Alternative Names: AAV9-ABCD1; AAV9-hABCD1; SBT-101 - SwanBio Therapeutics; SBT101

Latest Information Update: 28 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SwanBio Therapeutics
Class Adrenoleucodystrophy gene therapies; Gene therapies
Mechanism of Action ALDP expression stimulants; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Adrenomyeloneuropathy
New Molecular Entity No

Highest Development Phases

Phase I/II Adrenomyeloneuropathy

Most Recent Events

16 May 2025 Updated adverse events data from a I/II PROPEL trial in adrenomyeloneuropathy released by Spur Therapeutics
17 Jun 2024 SwanBio Therapeutics has been acquired by Spur Therapeutics
04 Oct 2023 SBT 101 receives Orphan Drug status for Adrenomyeloneuropathy in European Union, prior to October 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com